Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 11

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 11
---
 capital, capital expenditures and research and development and manufacturing expenses. See “Use of Proceeds” on page S-9.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Risk Factors                                     |     | You should read the “Risk Factors” section of this prospectus supplement, the accompanying prospectus and in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of factors to consider before deciding to purchase our common shares.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Nasdaq ticker symbol                             |     | “EDSA”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

The number of our common shares to be outstanding after the offering is
based on 7,037,648 of our common shares outstanding as of September 5, 2025 and excludes:

| · | 378,235 of our common shares issuable upon exercise of outstanding options granted under our equity incentive plans at a weighted 
 average exercise price of $24.71 per share;                                                                                       |

| · | 137,936 of our common shares issuable upon conversion of fully vested restricted stock units; |

| · | 1,124,171 of our common shares issuable upon conversion of unvested restricted stock units; |

| · | 680,846 of our common shares available for issuance or future grant pursuant to our equity incentive plan; |

| · | 435,414 of our common shares issuable upon the conversion of our Series A-1 Convertible Preferred Shares; |

| · | 4,343,750 of our common shares issuable upon the conversion of our Series B-1 Convertible Preferred Shares; and |

| · | 934,590 of our common shares issuable upon exercise of outstanding warrants at a weighted average exercise 
 price of $15.35 per share.                                                                                 |

| S-6 |

### RISK FACTORS
Before making an investment decision, you should carefully consider the risks described in this prospectus supplement, together with all of the other information incorporated by reference into this prospectus supplement and the accompanying prospectus, including the risks described in our most recent Annual Report on Form 10- K, as well as any amendments thereto reflected in subsequent filings with the SEC, including our audited consolidated financial statements and corresponding management’s discussion and analysis. The risks mentioned below are presented as of the date of this prospectus supplement and we expect that these will be updated from time to time in our periodic and current reports filed with or furnished to the SEC, as applicable, which are incorporated herein by